Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial - PubMed
2 hours ago
- #Clinical Trial
- #Dopamine Agonist
- #Parkinson's Disease
- Tavapadon is a novel, selective D1/D5 agonist investigated as adjunctive therapy to levodopa in Parkinson's disease (PD) patients with motor fluctuations.
- The TEMPO-3 trial was a phase 3, double-blind, placebo-controlled study involving 507 participants across 14 countries.
- Tavapadon significantly increased daily 'good-on-time' by 1.10 hours and reduced 'off-time' by 0.94 hours compared to placebo.
- The safety profile of tavapadon was favorable, with common adverse events including nausea (14.3%), dyskinesia (10.0%), and dizziness (7.6%).
- Most adverse events were mild to moderate and nonserious, occurring in 71.7% of tavapadon-treated participants versus 55.1% on placebo.